S2 Ep41: Cases & Conversations™: Transforming AML Care – Precision Strategies, Evolving Therapies, and Clinical Insights

PER Podcast Sessions

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; and Amer Zeidan, MBBS, MHS; discuss current best practices and emerging strategies in acute myeloid leukemia (AML) management.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess emerging treatment strategies for AML across frontline and relapsed/refractory settings
• Apply findings from recent clinical trials to optimize AML treatment approaches.
  

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Rigel Pharmaceuticals, Inc; Syndax Pharmaceuticals, Inc; and Taiho Oncology, Inc.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.

Instructions on How to Receive Credit

1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 5232
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.

You may immediately download your certificate.

Chair:

Gail J. Roboz, MD
Professor of Medicine
Director, Leukemia Program
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, NY
Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses Pharma, Genoptix GlaxoSmithKline, Geron, GlycoMimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, MorphoSys, NeoGenomics, Novartis, OncoPrecision, OncoVerity, Pfizer, Rigel, Roche, Syndax; Grant/Research Support: Janssen.

Faculty:

Hagop Kantarjian, MD
Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consultant: AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Pfizer, Takeda; Grant/Research Support: AbbVie, Amgen, Ascentage, Pfizer, Takeda.

Catherine Lai, MD, MPH
Associate Professor
Physician Leader, Leukemia Clinical Research Unit
University of Pennsylvania
Perelman Center for Advanced Medicine
Philadelphia, PA
Disclosures: Advisor: Arcellx, BioAscent, Daiichi Sankyo, Rigel, Servier, Syndax, Taiho Oncology; Consultant: AbbVie, Genentech, Rigel.

Amer Zeidan, MBBS, MHS

Professor of Medicine
Director of Hematologic Malignancies
Yale University School of Medicine
Yale Cancer Center
New Haven, CT
Disclosures: Consultant: AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, GlycoMimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, Zentalis; Grant/Research Support: AbbVie, Amgen, Astex, Bristol Myers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros.

Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on diagnostic workups, treatment sequencing, and proactive management of therapy-related toxicities in personalized care for patients with AML go to https://www.gotoper.com/annual-oncology-meeting-25-aml-activity
Release Date

July 30, 2025
Expiration Date

July 30, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.